Interesting

What does it mean to ‘eliminate’ viral hepatitis?

As the World Hepatitis Summit draws to a close today, Jeffrey V. Lazarus reflects on how the term ‘eliminate’ is currently understood in the field of viral hepatitis.

At the World Hepatitis Summit in Glasgow this week, it has been terrific to hear so many delegates talking so adamantly about the need to set our sights on viral hepatitis elimination.

While I am as excited as anyone about this prospect, I have some concerns about the language being used here and in the global health community at large. Do we all understand elimination in the same way?

My own conceptual framework is based on definitions established at the 1997 Dahlem Workshop on the Eradication of Infectious Diseases. To quote the summary of outcomes:

Elimination of disease: Reduction to zero of the incidence of a specified disease in a defined geographical area as a result of deliberate efforts; continued intervention measures are required. Example: neonatal tetanus.

Elimination of infections: Reduction to zero of the incidence of infection caused by a specific agent in a defined geographical area as a result of deliberate efforts; continued measures to prevent re-establishment of transmission are required. Example: poliomyelitis.

Eradication: Permanent reduction to zero of the worldwide incidence of infection caused by a specific agent as a result of deliberate efforts; intervention measures are no longer needed. Example: smallpox.

I have included the definition of eradication here because I have seen the term used in conjunction with viral hepatitis in ways that make me think some people regard viral hepatitis ‘elimination’ and ‘eradication’ as synonymous.

I have also seen calls for viral hepatitis elimination that seemed to be concerned entirely with hepatitis B and hepatitis C. If the global community is to commit itself to pursuing ‘viral hepatitis elimination’, what are the implications for how hepatitis A and hepatitis E should be addressed?

Adding a further terminology wrinkle, the World Health Organization (WHO) draft Global Health Sector Strategy on Viral Hepatitis, 2016–2021, which was published to serve as the basis of an ongoing consultation process, identifies a central goal in the following words:

Eliminate viral hepatitis as a major public health problem.

If you are wondering what this means, the draft strategy delineates specific targets, e.g. a 90% reduction in new hepatitis B infections by 2030 and a 70% reduction in hepatitis C incidence by 2030.

These are laudable goals, and I absolutely want to see the governments of the world invest the tremendous energy that will be required to achieve them. However, it is worth noting that the WHO draft strategy is not calling for viral hepatitis elimination as described above, and as many would understand it

Does any of this matter? That is, will inconsistent use of these terms undermine advocacy and public health efforts to end viral hepatitis? You tell me. I look forward to seeing this issue discussed further as we intensify our efforts to, ahem, end viral hepatitis.

Hepatology, Medicine and Policy is now accepting submissions. For more information, visit: www.hmap.biomedcentral.com.


Source: https://blogs.biomedcentral.com/on-health/2015/09/04/mean-eliminate-viral-hepatitis/

Inline Feedbacks
View all comments
guest

An interview with Luis Sordo del Castillo on the European Joint Action’s work on harm reduction

The Joint Action on HIV and Co-Infection Prevention and Harm Reduction (HA-REACT) addresses knowledge gaps in the prevention...

Snapshot from a revolution: ILC insights that caught my attention

Jeffrey V. Lazarus looks beyond the headlines to highlight some quietly important points that emerged at the recent...

Why do we continue to put our children at unnecessary risk of liver cancer?

On International Children’s Day (1 June), the World Hepatitis Alliance calls for widespread coverage of the hepatitis B...

Non-Alcoholic Fatty Liver Disease (NAFLD): Comprehensive Approach to Diagnosis, Treatment and Prevention of Metabolic Complications

Non-alcoholic fatty liver disease represents one of the most prevalent chronic liver conditions worldwide, affecting approximately twenty to...

An interview with Mika Salminen on the European Joint Action HA-REACT

The Joint Action on HIV and Co-Infection Prevention and Harm Reduction (HA-REACT) addresses knowledge gaps in the prevention...

Packing for INHSU? Bring a health systems perspective!

In advance of the 5th International Symposium on Hepatitis Care in Substance Users in Oslo, Norway, the Editor-in-Chief...

Liver Fibrosis Pathogenesis: Molecular Mechanisms and Cellular Interactions

Liver fibrosis represents one of the most complex and clinically significant pathological processes in hepatology, characterized by the...

INHSU? Gesundheit!

Hepatology, Medicine and Policy editor-in-chief Jeffrey Lazarus shares some reflections during the 5th International Symposium on Hepatitis Care...

Use hepatitis C elimination to fund harm reduction – and vice versa

The aim of the European Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) is to...

An interview with Piotr Wysocki and Iwona Wawer on the European Joint Action’s work from a Polish-partner perspective

The Joint Action on HIV and Co-Infection Prevention and Harm Reduction (HA-REACT) addresses knowledge gaps in the prevention...

What does it mean to ‘eliminate’ viral hepatitis?

As the World Hepatitis Summit draws to a close today, Jeffrey V. Lazarus reflects on how the term...

Невидимая борьба: как гепатит С влияет на психическое здоровье

Гепатит С — это не просто заболевание печени. Его воздействие на организм носит комплексный характер, затрагивая как физическое,...

Funding the war on hepatitis – deploying innovative finance mechanisms to eliminate hepatitis C in Europe

"In this blog, co-authors Rob Walton (Cello Health Public Affairs), Jeffrey V Lazarus (CHIP, WHO Collaborating Centre on HIV and...

Péter Sárosi on the struggle to fund harm reduction in Hungary

Following a workshop in Budapest on how to secure sustainable funding for harm reduction in Central and Eastern...

Why do we need a new hepatology journal?

Today, World Hepatitis Day, is a time for celebrating all forms of progress in combating this group of...

We can eliminate hepatitis C – but not without a plan

With the recent introduction of highly effective medicines, the world has made impressive strides toward eliminating the hepatitis...

Inspiration for sustainable funding – Harm Reduction in the New Environment

From the 4-6 April 2017, the Eurasian Harm Reduction Network (EHRN) is hosting the first Regional Conference for...

The International Network on Hepatitis in Substance Users: Striving to enhance access to testing, care, and treatment for people who use drugs

The International Network on Hepatitis in Substance Users (INHSU) is an international organization dedicated to scientific knowledge exchange,...

An interview with Heino Stöver on the European Joint Action’s work on infectious diseases in prisons

The Joint Action on HIV and Co-Infection Prevention and Harm Reduction (HA-REACT) addresses knowledge gaps in the prevention...

An interview with Emilis Subata on the European Joint Action’s work on sustainable & long-term funding for HIV, TB and HCV

The Joint Action on HIV and Co-Infection Prevention and Harm Reduction (HA-REACT) addresses knowledge gaps in the prevention...